In murine models, sequential administration of tafasitamab followed by CD19 CAR-T cells, after a defined washout period, preserved CAR-T expansion and cytotoxicity, and was associated with attenuated CRS compared to concurrent use. This evidence concerns the gene CD19 and congenital rubella syndrome.